Education
About Us
Working with TipRanks
Follow Us
GeneDx Holdings (WGS)
NASDAQ:WGS
WGS Stock Chart & Stats
$131.76
-$4.29(-4.42%)
At close: 4:00 PM EST
$131.76
-$4.29(-4.42%)
Day’s Range― - ―
52-Week Range$55.17 - $146.00
Previous CloseN/A
Volume338.68K
Average Volume (3M)525.57K
Market Cap
$3.81B
Enterprise Value$3.06B
Total Cash (Recent Filing)$155.08M
Total Debt (Recent Filing)$61.58M
Price to Earnings (P/E)2185.1
Beta1.04
Next Earnings
Mar 17, 2026EPS Estimate
0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.49
Shares Outstanding28,726,248
10 Day Avg. Volume584,818
30 Day Avg. Volume525,574
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)8.43
Price to Sales (P/S)6.77
P/FCF Ratio-60.81
Enterprise Value/Market Cap0.80
Enterprise Value/Revenue7.61
Enterprise Value/Gross Profit10.93
Enterprise Value/Ebitda125.81
Forecast
1Y Price Target
$151.90Price Target Upside15.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Earnings GrowthGeneDx reported third-quarter results that were well ahead of estimates and consensus, with significant revenue growth of 52% year-over-year.
Market ExpansionGeneDx was selected to participate in the Sunshine Genetics Network, the first state-backed newborn screening program, which could enhance its market position.
Revenue GuidanceThe company raised its 2025 revenue guidance, indicating confidence in continued strong performance.
Bears Say
Margin ForecastAlthough lower margin forecasts are anticipated due to increased costs, there is potential for margin recovery depending on the success in penetrating the pediatrician market.
Operating ExpensesOperating expenses increased over 20% relative to 2Q25, with further increases expected.
GeneDx Holdings News
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $55.17 and its highest was $146.00 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $3.81B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Mar 17, 2026 which is in 137 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Oct 28, 2025. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.423 by $0.067.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Undervalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.22.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 28,726,248 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.49 in its last earnings report, beating expectations of $0.423. Following the earnings report the stock price went up 5.212%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
GeneDx Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$151.90 (15.29% Upside)
$151.90 (15.29% Upside)
Blogger Sentiment
Bullish
WGS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 599.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $65.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.81%
12-Months-Change
Fundamentals
Return on Equity
0.84%
Trailing 12-Months
Asset Growth
20.81%
Trailing 12-Months
Company Description
GeneDx Holdings
GeneDx Holdings (WGS) is a leading genomic services company specializing in providing comprehensive genetic testing solutions for rare and inherited diseases. Operating primarily in the healthcare and biotechnology sectors, GeneDx offers a range of products and services including whole exome sequencing, whole genome sequencing, and targeted gene panels. The company focuses on delivering high-quality genomic data to clinicians and researchers, enabling improved patient care and advancing the understanding of genetic disorders.
WGS Company Deck
WGS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with significant revenue growth and improved margins. The FDA breakthrough designation adds further validation to GeneDx's technology. However, potential ASP declines and market underpenetration in NICUs were noted challenges. Overall, the highlights outweigh the lowlights, indicating a positive outlook.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$151.90
▲(15.29% Upside)
Technical Analysis
Evolent Health
―
10x Genomics
―
Certara
―
SOPHiA GENETICS
―
BrightSpring Health Services, Inc.
―
Ownership Overview
49.02% Insiders
17.99% Mutual Funds
0.09% Other Institutional Investors
23.53% Public Companies and Individual Investors